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Background: We previously showed that the long-acting beta agonist (LABA) salmeterol 
as inhalation powder or metered-dose inhaler improves lung-function parameters assessed by 
impulse oscillometry (IOS) in 2- to 5-year-old children with reversible-airway disease within 
15 minutes.
Objective: We studied 12- to 45-year-olds with mild persistent asthma in order to compare the 
onset and extent of peripheral airway effects following the first dose and after 4 weeks dosing 
with two inhaled corticosteroid (ICS)/LABA combinations: fluticasone propionate/salmeterol 
115/21 and budesonide/formoterol 160/4.5.
Methods: Thirty subjects with mild persistent asthma using only an as-needed short-acting 
beta-agonist (albuterol) who had at least a 40% change in integrated low-frequency reactance 
postalbuterol were selected and randomized to receive either fluticasone propionate/salmeterol 
or budesonide/formoterol (15 subjects each). We collected three to six IOS replicates at base-
line, at 5, 20, 40, 60, 120, and 240 minutes postdose at randomization, and after 4 weeks of 
twice-daily dosing. Blinded investigators calculated IOS frequency-dependent resistance and 
reactance (R5–R20 and AX), indicative of small-airway dysfunction, and also estimated the 
peripheral airway resistance (R
p
) and peripheral airway compliance (C
p
), using a respiratory-
impedance model.
Results: At randomization visits, onset of action was detected as early as 5 minutes (t-test, 
P , 0.05) after fluticasone propionate/salmeterol by C
p
, and within 5 minutes after budesonide/
formoterol by R5–R20, AX, R
p
, and C
p
. However, after 4 weeks of dosing, only R
p
 was significantly 
different (from 60 to 120 minutes) after fluticasone propionate/salmeterol, while R5–R20, AX, 
R
p
, and C
p
 were not significantly different within 240 minutes after budesonide/formoterol.
Conclusion: These two ICS/LABA combinations initially improved the peripheral airway func-
tion of 12- to 45-year-old asthmatics significantly in about 5 minutes or less, as measured by 
R5–R20, AX, R
p
, and/or C
p
. After regular dosing for 4 weeks, pre- to postdose differences in these 
parameters had diminished significantly due to improved predose status of peripheral airways. 
Single dosing with ICS/LABA combinations in mild persistent asthma improves small-airway 
function, and the effect is maintained over a 12-hour interval by regular use for 4 weeks.
Keywords: asthma, ICS/LABA combination, impulse oscillometry parameters, lung-model 
parameters, peripheral airway resistance, peripheral airway compliance
Introduction
Previous work has revealed a heretofore-unrecognized early effect, ie, in under 
15 minutes, of Serevent (salmeterol xinafoate) from a Diskus (inhalation powder) and 
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a metered-dose inhaler (MDI) in 2- to 5-year-old children 
with reversible airflow obstruction, assessed by forced oscil-
lation (IOS).1 They had been selected for that study based on 
demonstrated brisk response to the short-acting beta agonist 
(SABA) albuterol at screening. Statistically significant 
changes in airway mechanics were evident at 5 minutes, aug-
menting over the subsequent 55 minutes, and sustained for the 
next 8 hours, based on IOS measurements at 5, 30, 60, 120, 
240, and 480 minutes after drug administration. The change 
was more prominent with Serevent MDI at 5 and 30 minutes 
in small airways, while that with Serevent Diskus was more 
prominent in large airways at these time points. While such 
rapid onset of action is comparable to reports of formoterol 
onset of action in adults,2 it has not been shown that similar 
early action of salmeterol can be detected by IOS in older 
children and adults. Moreover, whether and how salmeterol 
differs from formoterol in terms of central and peripheral 
airway effects are as yet unanswered questions.
The present study’s objectives were to obtain IOS param-
eters, and also to estimate lung-component properties that 
reflect small-airway dysfunction (both resistive and elastic 
components), at baseline and after a single dose in order to 
compare the onset of drug action. We hypothesized that mea-
surements using current IOS hardware and software along 
with recently implemented augmentation of measurement 
techniques, ie, lung model-parameter estimation, would be 
sensitive enough to detect an early response to Advair hydro-
fluoroalkane (HFA) MDI (fluticasone propionate/salmeterol 
115/21) and provide evidence of improved small-airway 
mechanics at time points comparable to those for Symbi-
cort pressurized metered-dose inhaler (pMDI; budesonide/
formoterol 160/4.5). Furthermore, we asked to what extent 
either or both inhaled corticosteroid (ICS)/long-acting beta 
agonist (LABA) combinations would still produce early and 
significant responses after 4 weeks of dosing, since a per-
sistent beneficial effect on small-airway dysfunction would 
support the earlier and regular use of these agents in patients 
with mild persistent asthma.3
Methods
Protocol
The patients were 12–45 years old with mild persistent 
asthma as defined by Global Initiative on Asthma/National 
Institutes of Health guidelines. They were recruited either 
from the clinic population of the Asthma and Allergy  Center 
of El Paso or through advertising at area colleges. They 
had to have had at least a 1-year history of asthma requir-
ing SABA (albuterol) as needed, with the addition of short 
courses of inhaled corticosteroids or oral corticosteroids 
in the preceding year. Subjects with respiratory infections 
within the prior 6 weeks, and those using inhaled and/or 
systemic corticosteroids or leukotriene antagonists within the 
previous month were excluded, as were those maintained on 
controllers for .6 months in the prior year. Other excluded 
medications included LABA or oral antihistamines within 
24 hours of each visit. At screening, subjects were assessed by 
routine IOS measures (three to four replicates) at baseline and 
20 minutes after SABA HFA pMDI (up to six inhalations). 
Those who manifested .40% decrease in IOS frequency-
dependent reactance (AX) were enrolled and scheduled for 
randomization (to Advair or Symbicort) within 1–7 days. On 
visit 2, two puffs of the study drug were administered and IOS 
measurements performed, after which subjects were given 
open-label supplies of either drug and instructed to inhale two 
puffs twice a day for 4 weeks. To assure .80% compliance 
with dosing, subjects were phoned every week, and their 
drug canisters weighed. Finally, on visit 3, all  measurements 
undertaken on visit 2 were repeated. This study was con-
ducted in accordance with the amended  Declaration of 
 Helsinki, and the protocol was approved by the Chesapeake 
IRB (Pro00002852) in June 2009; its  ClinicalTrials.gov 
identifier is NCT00867737.
On visits 2 and 3, a review of recent medical history 
and measurement of vital signs were performed. Extended 
baseline IOS measurements (six replicates) were followed 
by dosing and serial IOS measurements over 240 minutes. 
Heart rate and respiratory rate were recorded at 5, 20, 40, 
60, 120, and 240 minutes; immediately after each of these 
recordings, postdose IOS measurements (three replicates 
each) were performed. For safety and reproducibility, drugs 
were administered under supervision and subjects observed 
while gargling immediately postdose.
Outcome measures (at each postdose time point) 
included:
•	 IOS measures R5–R20 and AX
•	 model-derived estimates of large and small airways’ 
resistance and compliance.
The available IOS measures included AX and total respi-
ratory system resistance R and reactance X at 3, 5, 10, 15, 
20, and 25 Hz (R3, … R25; X3, … X25), which yielded 
R5–R20. In addition, the twelve frequency-dependent R 
and X  measures were fitted to an equivalent electrical model 
(analog) of the respiratory system to derive estimates of its 
constituent resistance, inertance, and compliance values.
Paired t-tests compared each patient’s baseline IOS 
AX and R5–R20 parameters, and each patient’s baseline 
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large- and small-airway resistance and compliance estimates, 
at visits 2 and 3, with the same at each postdose time point. 
Statistical significance represented by P , 0.05 was used to 
determine onset of action.
Demographics
Of 96 candidates screened, 31 were enrolled based on the 
aforementioned criteria; informed written consent was 
obtained from all patients for the treatment/testing and for 
their medical data to be used in this study. However, one 
subject withdrew, very early, so only 30 subjects completed 
the study. Their demographics were: 15 male, 15 female, ages 
12–45 (26.5 ± 11.5) years, height 142–181 (163.0 ± 9.6) cm, 
and weight 32.5–150.2 (82.2 ± 23.2) kg. Advair or Symbicort 
was randomly administered to 15 subjects each; the specific 
drug assignment was not revealed to the data analysts until 
they completed all IOS calculations and model-parameter 
estimations.
Data analysis and modeling
The IOS parameters R5–R20 and AX, representing low-
frequency dependence of resistance4 and integrated low-fre-
quency reactance area,5 respectively, were obtained directly 
from the test readouts of all the 30 subjects; no adverse 
events occurred, and all data were of sufficient quality and 
consistency. With a little more effort, the respiratory system’s 
aggregated small-airway resistance (R
p
) and small-airway 
compliance (C
p
) were estimated assuming the augmented 
RIC (aRIC) model,6 which also includes the large-airway 
resistance (R) and inertance (I), and extrathoracic upper-
airway compliance (C
e
); the estimates being those values 
producing the best least-squares fit to the given (R3, … R25; 
X3, … X25).6 Then, paired t-tests were applied to compare 
the IOS parameters as grouped by administered drug, visit 
number, and time point. This same procedure was applied 
to the aRIC model estimates of R
p
 and C
p
.
Results
The mean values of R5–R20 and AX and of R
p
, and C
p
 at 
baseline and each postdose time point are shown in Table 1. 
The results of paired t-tests comparing R5–R20 and AX at 
each postdose time point to baseline values are plotted in 
Figures 1 and 2, and those of comparing R
p
 and C
p
 at each 
time point to baseline values in Figures 3 and 4.
For the randomization visits, onset of action was detected 
from R5–R20 and AX (P , 0.05) between 5 and 20 minutes 
after Advair and by 5 minutes after Symbicort, the effects 
being uniformly sustained through 240 minutes by both 
medications. During the final visits, onset of action was 
detected from AX between 5 and 20 minutes after Advair and 
was sustained up to 240 minutes, whereas no onset of action 
could be detected post-Symbicort over 240 minutes.
From the model estimates, onset of action during the 
randomization visits was detected by C
p
 between 5 and 
20 minutes after Advair (P , 0.05), and by 5 minutes after 
Symbicort (based on C
p
 and also R
p
, P , 0.05), the effects 
being uniformly sustained through 240 minutes by both 
medications. During the final visits, onset of action was 
detected from R
p
 between 40 and 60 minutes after Advair, 
and this was sustained to between 120 and 240 minutes, 
whereas no onset of action could be detected from C
p
 and 
R
p
 post-Symbicort over 240 minutes.
Discussion
We had hypothesized that Advair HFA MDI 115/21 would 
produce an earlier than expected response in asthmatic 
Table 1 Mean values of impulse oscillometry system frequency-dependent resistance (r5–r20; cmh2O/l/s) and reactance AX 
(cmh2O/l), peripheral airway resistance (Rp; cmh2O/l/s), and peripheral airway compliance (Cp; l/cmh2O) at baseline (Bl) and each 
time point after administration of Advair or Symbicort during the randomization and final visits
Advair (randomization visit) Symbicort (randomization visit)
BL 5 20 40 60 120 240 BL 5 20 40 60 120 240
r5–r20 0.204 0.159 0.126 0.114 0.113 0.127 0.129 0.259 0.113 0.108 0.112 0.097 0.096 0.098
AX 1.526 1.122 0.774 0.692 0.660 0.759 0.763 2.332 0.643 0.597 0.663 0.554 0.537 0.536
Rp 0.547 0.503 0.423 0.425 0.396 0.409 0.394 0.689 0.397 0.380 0.403 0.372 0.356 0.359
Cp 0.084 0.114 0.138 0.141 0.146 0.135 0.139 0.067 0.134 0.161 0.143 0.152 0.162 0.163
Advair (final visit) Symbicort (final visit)
BL 5 20 40 60 120 240 BL 5 20 40 60 120 240
r5–r20 0.164 0.135 0.119 0.111 0.118 0.118 0.123 0.127 0.101 0.094 0.099 0.099 0.096 0.096
AX 1.171 0.841 0.663 0.613 0.594 0.606 0.687 0.833 0.571 0.551 0.554 0.545 0.526 0.529
Rp 0.472 0.429 0.406 0.387 0.372 0.361 0.405 0.426 0.406 0.399 0.385 0.370 0.350 0.364
Cp 0.115 0.130 0.141 0.150 0.147 0.147 0.139 0.136 0.166 0.165 0.161 0.163 0.168 0.169
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teenagers and young adults, at times comparable to those for 
Symbicort pMDI 160/4.5. Even mild asthma is primarily a 
small-airway disease, hence this study’s outcome-measures 
focus on those IOS parameters (R5–R20, AX) and respiratory 
system model estimates (R
p
, C
p
) that reflect small-airway 
mechanics.5,6 Note that in general, in all subjects, dosing 
resulted in lower R5–R20, AX, and R
p
 values and higher C
p
 
values, consistent with improved small-airway mechanics 
and therefore reduced airflow obstruction.3
Our data indicate that Symbicort acted slightly more 
quickly than Advair during visit 2 (steroid-naïve condition). 
This resembles previous studies comparing similar medica-
tions, such as Palmqvist et al,2 who studied 30 asthmatic 
adults (28–73 years old) administered budesonide/formoterol 
(160/4.5) or salmeterol/fluticasone (50/250) or placebo 
using spirometric measurements (forced expiratory volume 
in 1 second [FEV
1
]); onset of action, significantly different 
from placebo, was reported by 3 minutes and by 15 minutes, 
respectively. Our data also show that R5–R20 and C
p
 were 
the more sensitive indicators of drug action.
However, after 4 weeks of dosing, the drugs’ effects 
were muted, with Symbicort showing less action than 
Advair. This is probably due to a 64% decrease in base-
line AX (2.33–0.83 cmH
2
O/L) for the Symbicort group 
over that period, whereas baseline AX decreased only 26% 
(1.53–1.13 cmH
2
O/L) during the same time-frame in the 
Advair group, ie, Symbicort produced greater long-term 
improvement in small-airway mechanics than Advair. Box 
plots of the individual AX values, grouped by medication, 
are shown in Figure 5 to illustrate their statistical relation-
ships over time. Note that 60 minutes postdose during the 
randomization visits is roughly when the two groups (on 
average) showed the most significant reduction in AX, while 
during the final visits this nadir was reached slightly later, 
at about 120 minutes.
Similarly, the change in baseline R5–R20, C
p
, and 
R
p
 between visits for the Symbicort group was 51% (0.259–
0.127 cmH
2
O/L/s), 101% (0.0674–0.1355 L/cmH
2
O), and 
38% (0.6891–0.4265 cmH
2
O/L/s), respectively, versus 20% 
(0.204–0.164 cmH
2
O/L/s), 37% (0.0840–0.1147 L/cmH
2
O), 
0.01
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Figure 1 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [r5–r20], *, and reactance [AX], ) at each time point after administration 
of Advair or symbicort during randomization visits compared to the patients’ baseline r5–r20 and AX values (0.204 cmh2O/l/second and 1.526 cmh2O/l, respectively, for 
Advair; 0.259 cmh2O/l/second, and 2.332 cmh2O/l, respectively, for symbicort) during the same visit (n = 15 for each group).
0
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Figure 2 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [r5–r20], *, and reactance [AX], ) at each time point after administration 
of Advair or Symbicort during final visits compared to the patients’ baseline R5–R20 and AX values (0.164 cmh2O/l/second and 1.171 cmh2O/l, respectively, for Advair; 
0.127 cmh2O/l/second and 0.833 cmh2O/l, respectively, for symbicort) during the same visit (n = 15 for each group).
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and 14% (0.5474–0.4716 cmH
2
O/L/s), respectively, for the 
Advair group. Figures 6–8 show box plots of the individual 
R5–R20, C
p
, and R
p
 values, respectively, grouped by medica-
tion, to illustrate their statistical relationships over time.
Comparing the various parameters over time, the other 
findings can be summarized as follows:
•	 During the randomization visits, Symbicort pro-
duced greater bronchodilation at 5 minutes than 
Advair. Since baseline AX = 2.33 cmH
2
O/L and 
R5–R20 = 0.259 cmH
2
O/L/second for the Symbi-
cort group, and baseline AX = 1.53 cmH
2
O/L and 
R5–R20 = 0.204 cmH
2
O/L/second for the Advair group, 
the Symbicort group had slightly worse lung function than 
the Advair group, but at 5 minutes post-study drug, values 
were AX = 0.643 cmH
2
O/L and R5–R20 = 0.113 cmH
2
O/L/
second for the Symbicort group, and AX = 1.12 cmH
2
O/L 
and R5–R20 = 0.159 cmH
2
O/L/second for the Advair 
group. The same implications can be gathered from the 
R
p
 and C
p
 values at baseline for the Symbicort group 
(0.689 cmH
2
O/L/second, 0.0674 L/cmH
2
O) and Advair 
group (0.547 cmH
2
O/L/second, 0.0840 L/cmH
2
O), and 
at 5 minutes post-study drug for the Symbicort group 
(0.397 cmH
2
O/L/second, 0.1340 L/cmH
2
O) and Advair 
group (0.503 cmH
2
O/L/second, 0.1138 L/cmH
2
O).
•	 During the final visits, Symbicort produced lesser bron-
chodilation at 5 minutes than Advair. Since baseline 
AX = 0.83 cmH
2
O/L and R5–R20 = 0.127 cmH
2
O/L/second 
for the Symbicort group, and baseline AX = 1.13 cmH
2
O/L 
and R5–R20 = 0.164 cmH
2
O/L/second for the Advair 
group, the Symbicort group’s lung function had become 
better than the Advair group’s lung function after 4 weeks 
of treatment. So the Symbicort group had less room to 
respond to bronchodilator/anti-inflammatory action. This 
was corroborated by the smaller baseline R
p
 and larger 
baseline C
p
 for the Symbicort group (0.426 cmH
2
O/L/
second, 0.1355 L/cmH
2
O) compared to the Advair group 
(0.472 cmH
2
O/L/second, 0.1147 L/cmH
2
O).
•	 For the randomization visits, change in R5–R20 was 
greater than change in AX at all-time points for both drugs. 
However, for the final visits, this order was reversed. 
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Figure 3 t-test P-values of model estimates (peripheral airway resistance [Rp], ; peripheral airway compliance [Cp], ×) at each time point after administration of Advair 
or symbicort during randomization visits compared to the patients’ baseline Rp and Cp values (0.547 cmh2O/l/second and 0.084 l/cmh2O, respectively, for Advair; 
0.689 cmh2O/l/second and 0.067 l/cmh2O, respectively, for symbicort) during the same visit (n = 15 for each group).
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Figure 4 t-test P-values of model estimates (peripheral airway resistance [Rp], ; peripheral airway compliance [Cp], ×) at each time point after administration of Advair or 
Symbicort during final visits compared to the patients’ baseline Rp and Cp values (0.472 cmh2O/l/second and 0.115 l/cmh2O, respectively, for Advair; 0.426 cmh2O/l/second 
and 0.136 l/cmh2O, respectively, for symbicort) during the same visit (n = 15 for each group).
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Hence, long-term ICS/LABA use appears to fundamen-
tally modify lung mechanics, resulting in less asynchro-
nous behavior (improved time constants).
•	 For the randomization visits, the change in C
p
 was greater 
than the change in R
p
 at all-time points for both drugs. 
However, for the final visits, this order was reversed, 
and the change in R
p
 was greater than the change in C
p
 
at all-time points for Advair and after 40 minutes for 
Symbicort. It seems plausible to attribute these changes 
to the anti-inflammatory effects of inhaled corticoster-
oids, particularly on the small-airway walls’ compliance. 
This suggests that the respiratory system model provides 
additional information regarding small-airway mechan-
ics that is not conveyed by either R5–R20 or AX, although 
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Figure 5 Box plots of the individual impulse oscillometry frequency-dependent 
reactance (AX) values at two time points each during the randomization visits (Vr) 
and the final visits (VF) for (A) the Advair group and (B) the symbicort group.
Abbreviation: Bl, baseline.
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Figure 6 Box plots of the individual impulse oscillometry frequency-dependent 
resistance (r5–r20) values at two time points each during the randomization visits 
(VR) and the final visits (VF) for (A) the Advair group and (B) the symbicort group.
Abbreviation: Bl, baseline.
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Figure 7 Box plots of the individual peripheral airway compliance (Cp) values at two 
time points each during the randomization visits (VR) and the final visits (VF) for 
(A) the Advair group and (B) the symbicort group.
Abbreviation: Bl, baseline.
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R
p
 and C
p
 seem less sensitive for detecting changes in 
small-airway function. Moreover, R
p
 and C
p
 exhibit dif-
ferent aspects of the physiological effects of these drugs, 
especially Symbicort, as seen in Figures 3 and 4.
•	 It appears that Symbicort produces a biphasic effect 
on lung mechanics, ie, a quick-phase effect from about 
5 to 30 minutes postdose, and a slow-phase effect from 
about 50 minutes to over 240 minutes postdose. This can 
be observed in both visits’ results for AX and R5–R20 
 (Figures 1 and 2), and for R
p
 and C
p
 (Figures 3 and 4). 
Its cause is uncertain, although one may hypothesize that 
formoterol has quite different pharmacodynamics than 
budesonide. Previous studies investigating Symbicort’s 
onset and/or duration of action2,7–11 were consulted. Data 
presented by Palmqvist et al2 for asthmatic adults and by 
Lindberg et al10 for chronic obstructive pulmonary disease 
in adults (Figures 9 and 10) show an inflection in the change 
from baseline FEV
1
 value occurring between 5 and 10 min-
utes and between 10 and 20 minutes, respectively, although 
Figure 9 also shows an inflection in that time range for the 
placebo group. Although neither paper suggested a pos-
sible biphasic action, their results and ours indicate that the 
parameters’ inflections are due not to random variations 
but some real physiological phenomenon.
Conclusion
Advair HFA MDI 115/21 produced a significant response 
almost as early as Symbicort pMDI 160/4.5 after a single 
dose in 12- to 45-year-old mild asthmatics, as determined 
by IOS parameters and lung-model estimates: between 5 
and 20 minutes versus less than 5 minutes, respectively. 
This finding was consistent whether one considered R5–R20 
or AX or C
p
 or R
p
, which are all associated with peripheral 
(small) airway mechanics.
Moreover, after 4 weeks of dosing, there was evidence 
that both ICS/LABA combinations had produced significant 
sustained improvement in peripheral airway parameters. 
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Figure 8 Box plots of the individual peripheral airway resistance (Rp) values at two 
time points each during the randomization visits (VR) and the final visits (VF) for 
(A) the Advair group and (B) the symbicort group.
Abbreviation: Bl, baseline.
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Figure 9 Mean forced expiratory volume in 1 second (FeV1) during the first 
180 minutes after inhalation of budesonide/formoterol (pressurized metered-dose 
inhaler [pMDi] 2 × 160/4.5 mg), salmeterol/fluticasone (pMDI 2 × 25/250 mg), 
salbutamol (2 × 100 mg), or placebo (percentage increase from predrug value). 
copyright © 2001, elsevier. Palmqvist M, Arvidsson P, Beckman O, Peterson s, 
lötvall J. Onset of bronchodilation of budesonide/formoterol vs salmeterol/
fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14(1):29–34.2
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Figure 10 Percent change in forced expiratory volume in 1 second (FeV1) up to 
15 minutes and 3 hours with the combination of budesonide/formoterol (one or 
two inhalations) (160/4.5 mg) compared with the combination salmeterol/fluticasone 
(50/250 mg) and placebo. reprinted from lindberg et al,10 with permission from John 
Wiley and sons.
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This improvement resulted in diminished predose-to-postdose 
differences, with Symbicort improving steady-state lung 
function slightly more than Advair. It was somewhat surpris-
ing that there was no further improvement in small-airway 
parameters when comparing single to steady-state dosing. 
These findings could still have real-world clinical importance 
in that the sustained amelioration of small-airway dysfunction 
(decreased obstruction and improved compliance) noted in 
these mild asthmatic subjects could lead to meaningful clini-
cal benefits based on the documented association between 
small-airway dysfunction and asthma control.3
Finally, a biphasic effect of Symbicort on lung func-
tion was observed that has heretofore been unnoted. Since 
earlier studies’ data provide additional evidence that this is 
a real phenomenon, further investigation as to its basis and 
implications seems warranted.
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